Stocks that outperform the market usually share key traits such as rising sales, expanding margins, and increasing returns on capital. The select few that can do all three for many years are often the ones that make you life-changing money.

The bottom line is that over the long term, earnings growth goes hand in hand with the biggest winners. Taking that into account, here are three market-beating stocks that could turbocharge your returns.

Nova (NVMI)

Five-Year Return: +383%

Headquartered in Israel, Nova (NASDAQ: NVMI) is a provider of quality control systems used in semiconductor manufacturing.

Why Should You Buy NVMI?

1. Market share has increased this cycle as its 26.3% annual revenue growth over the last two years was exceptional
2. Earnings growth has massively outpaced its peers over the last five years as its EPS has compounded at 33.1% annually
3. Strong free cash flow margin of 28% enables it to reinvest or return capital consistently

Nova is trading at $333.93 per share, or 35.8x forward P/E. Is now the right time to buy? See for yourself in our comprehensive research report, it’s free for active Edge members .

DXP (DXPE)

Five-Year Return: +423%

Founded during the emergence of Big Oil in Texas, DXP (NASDAQ: DXPE) provides pumps, valves, and other industrial components.

Why Are We Bullish on DXPE?

1. Annual revenue growth of 13% over the last five years was superb and indicates its market share increased during this cycle
2. Operating margin improvement of 5.1 percentage points over the last five years demonstrates its ability to scale efficiently
3. Share buybacks catapulted its annual earnings per share growth to 27.4%, which outperformed its revenue gains over the last two years

DXP’s stock price of $115.08 implies a valuation ratio of 18x forward P/E. Is now a good time to buy? Find out in our full research report, it’s free for active Edge members.

Natera (NTRA)

Five-Year Return: +114%

Founded in 2003 as Gene Security Network before rebranding in 2012, Natera (NASDAQ: NTRA) develops and commercializes genetic tests for prenatal screening, cancer detection, and organ transplant monitoring using its proprietary cell-free DNA technology.

Why Are We Backing NTRA?

1. Tests Processed averaged 19.6% growth over the past two years and imply healthy demand for its products
2. Adjusted operating profits increased over the last two years as the company gained some leverage on its fixed costs and became more efficient
3. Free cash flow flipped to positive over the last five years, showing the company has crossed a key inflection point

At $235.46 per share, Natera trades at 12.8x forward price-to-sales. Is now the time to initiate a position? See for yourself in our full research report, it’s free for active Edge members.

High-Quality Stocks for All Market Conditions

The market’s up big this year - but there’s a catch. Just 4 stocks account for half the S&P 500’s entire gain. That kind of concentration makes investors nervous, and for good reason. While everyone piles into the same crowded names, smart investors are hunting quality where no one’s looking - and paying a fraction of the price. Check out the high-quality names we’ve flagged in our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today.